Last reviewed · How we verify
ON01910 Na
At a glance
| Generic name | ON01910 Na |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC (EARLY_PHASE1)
- Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (PHASE3)
- Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine (PHASE1, PHASE2)
- Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs (PHASE2)
- Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia (PHASE2)
- Three Dosing Schedules of Oral Rigosertib in MDS Patients (PHASE1)
- Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts (PHASE3)
- Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ON01910 Na CI brief — competitive landscape report
- ON01910 Na updates RSS · CI watch RSS
- National Heart, Lung, and Blood Institute (NHLBI) portfolio CI